欧å·å§å¡ä¼ã¯2011å¹´ãã¨ççã«å¯¾ããBSEã¢ãã¿ãªã³ã°æ¤æ»ã®å¯¾è±¡æé½¢ã72ãæé½¢ã«å¼ãä¸ãããã¨ã決å®ãã2013å¹´1æ1æ¥ããæ½è¡ããã¦ããã 欧å·å§å¡ä¼ã¯ã2013å¹´2æ4æ¥ã«BSEã®ã¢ãã¿ãªã³ã°æ¤æ»ã«ä¿ãæ¹æ£ï¼æ¡ä»¶ç·©åï¼ãè¡ããåå çå½ã®2013å¹´7æ5æ¥æç¹ã®ç¶æ³ãçºè¡¨ãããã ã»ç·ã®å çå½ï¼å¥åº·ã¨ççã«å¯¾ããæ¤æ»ã¯å¿ è¦ãªã ï¼ãã«ã®ã¼ããã§ã³ããã³ãã¼ã¯ãã¨ã¹ããã¢ãã¢ã¤ã«ã©ã³ããã¤ã¿ãªã¢ãã©ããã¢ãã«ã¯ã»ã³ãã«ã°ããã³ã¬ãªã¼ããªã©ã³ãããªã¼ã¹ããªã¢ãã¹ãããã¢ããã£ã³ã©ã³ããã¹ã¦ã§ã¼ãã³ãè±å½ï¼ ã»éã®å çå½ï¼2013å¹´ä¸ã«ã¨ççã«å¯¾ããæ¤æ»ãå»æ¢ããäºå® ï¼ã¹ãã¤ã³ããªãã¢ãã¢ï¼ ã»é»ã®å çå½ï¼ã¨ççã®æ¤æ»é æ°ãåæ¸ ï¼ãã¤ãããããã¹ï¼ ã»èµ¤ã®å çå½ï¼ã¨çç72ãæ齢以ä¸ã®æ¤æ»ãå®æ½ ï¼ã®ãªã·ã£ããã©ã³ã¹ããã«ã¿ããã¼ã©ã³ãããã«ãã¬ã«ãã¹ãããã¢ï¼ ã»ã°ã¬ã¤ã®å çå½ï¼å½
å·çè å®è°· æ 油糧種åè¼¸å ¥é¢ä¿ã®ä»äºæãéºä¼åçµã¿æãä½ç©ã»é£åã®å½éååã«ã¤ãã¦æ å ±åéã»åæãè¡ã£ã¦ãã GMOã¯ã¼ã«ãâ ¡ å®è°· æ 2013å¹´7æ8æ¥ æææ¥ ãã¼ã¯ã¼ãï¼ãã¤ã㯠ã¡ãã£ã¢ ç°å¢ è¾²è¬ ã風è»ã«çªæããã®ã¯éçç£çã§ããã¨ããMonsantoãã¤ãæ¯ç¤¾åºå ±æ å½è Ursula Lüttmer-Ouazane女å²ã®å°è±¡çãªæå¦çä¿®è¾ãä¼´ãããMonsanto gives up fight for GM plants in Europeããªã©ã¨ããè¦åºããä¸çã®åç´ãè³ãããã®ã¯ã2013å¹´5æ31æ¥ããæ°æ¥éã ã£ãã Monsanto社ããã¨ã¼ãããã«ããã¦GMï¼éºä¼åçµã¿æãï¼ä½ç©ãåºãã試ã¿ãæ念ããï¼æ°è¦æ ½å¹æ¿èªç³è«ãããªãã製åè¼¸å ¥ã¨é£æã»é£¼æã¸ã®å©ç¨æ¿èªç³è«ã¯ç¶ç¶ï¼ãã¨ããã®ãåç´ã«ãã解éï¼æ£ç¢ºã«ã¯Tazç´ã®æ å ±ã«ããã°ãã¨æã£ã¦ãããï¼ã ãã¤ã¾ããæ å ±
å·çè ç½äº æ´ä¸ 1955å¹´çã¾ããä¿¡å·å¤§å¦è¾²å¦é¨ä¿®å£«èª²ç¨ä¿®äºå¾ã害è«é²é¤ãéºä¼åçµæãä½ç©ã®ç°å¢å½±é¿è©ä¾¡ã«å¾äºã2011å¹´éè·ãç¾å¨ããªã¼ è¾²ã¨é£ã®å¨è¾ºæ å ± ç½äº æ´ä¸ 2013å¹´7æ3æ¥ æ°´ææ¥ ãã¼ã¯ã¼ãï¼ãã¤ã㯠ã¢ãã¾ã³ç±å¸¯æã®éæ³ä¼æ¡ãç¦æ¢ãããã©ã¸ã«å½å æ³ï¼æ³å®ã¢ãã¾ã³ï¼ã®ææããæè¿ã¯ç±å¸¯æã®ä¼æ¡é¢ç©ã¯ããæ¸ã£ã¦ããããããã§ãå°ç温æåã®åå ã¨ããã温室å¹æã¬ã¹ã®å¸åæºã¨ãã¦ã¢ãã¾ã³ç±å¸¯æãå®ãã¨è¨ãä¸çã®å£°ã¯å¼·ãã ä¸å½ãªã©æ°èå½ã®é£çæ´»ã¬ãã«ã®åä¸ã§ã家ç飼æã®ãã¤ãºãçèã®è¼¸åºãå¢ãããã¤ãºçãç§èå°ã«å¤ãã£ãããã¨ããã®ãç±å¸¯ææ¸å°ã®çç±ã«ãªã£ã¦ããããä¸ææããã©ã¸ã«ããã¨ã¼ãããã¸ã®ãã¤ãºãçèã®è¼¸åºãæ¥å¢ãããããã«ã¯ã¨ã¼ãããã§çºçããBSEï¼ç海綿ç¶è³çï¼ãé¢ä¿ãã¦ãããã¨ã¯ãã¾ãå ±ãããã¦ããªãã 人éã®æ¶è²»æ´»åã¨ç±å¸¯æä¼æ¡ã®é¢ä¿ãåæ ä»å¹´ï¼201
æ¯æ¥é£åã«ä¸ãé£åãé£æã¨ãªããã®ï¼ä¾ãã°é£èã¨ãã¦ä¾ããã家çã®é£¼æãªã©ï¼ã®å®å ¨æ§ã確ä¿ãããã¨ã¯ãã©ã®å½ã«ã¨ã£ã¦ãæãéè¦ãªæ½çã®ã²ã¨ã¤ã ãåä¸å¸å ´ãç®æã欧å·é£åï¼EUï¼ã ããå çå½ãã¨ã«æ°å風åã¯ãã¡ãããé£æåãéããå½ç¶ãå®å ¨æ§ã®å®ç¾©ããã¤ã¦ã¯å½ã«ãã£ã¦ç°ãªã£ã¦ãããEUã¯ãããã£ãç¸éã課é¡ãä¹ãè¶ãã¦ãå çå½å ¨ä½ã«åãå ¥ããããå ±éã®åºæºã»å¶åº¦ã»æ³å¾ãä½ãä¸ããå¹æçãªéç¨ãä¿é²ãã¦ããã å ¨ä½ãè¦éã«ç½®ãããé£åå®å ¨é¢é£æ³ãã¯ãªãã£ã çµæ¸çãªçµ±åãä¸å¿ã«çºå±ãã¦ãã欧å·å ±åä½ï¼ECï¼ããæ¿æ²»ã»å¤äº¤é¢ãå«ããçµ±åãç®æã欧å·é£åï¼EUï¼ã«çã¾ãå¤ãã£ãã®ã¯1993å¹´11æãå½æ12ã«å½ã ã£ãå çå½ã¯ã2004å¹´5æã«ä¸ã»æ±æ¬§10ã«å½ãä¸æ°ã«å ãããªã©ãå¢ãç¶ããæ¬å¹´7æã®ã¯ãã¢ãã¢ã®å çããã£ã¦28ã«å½ã¨ãªãã 人å£5å5,000ä¸äººï¼2011å¹´ï¼ãåç®å½å ç·çç£ï¼GDP
ãã¤ããã¥ã¼ã¹ãã¤ã¸ã§ã¹ãã17 Mai 2013 Nr.954 æ¥æ¬ã®TPP交æ¸åå ã決å®ãããTPPã¨ã¯ãç°å¤ªå¹³æ´ã®å½ã ã«ãããçµæ¸é£æºåå®ã®ãã¨ã§ãããæ£å¼å称ã¯Trans-Pacific Partnershipãæ¥æ¬ã®äº¤æ¸åå ã«ã¯ãåå çå½ã¨ç¾å¨äº¤æ¸ã«åå ãã¦ããå ¨11ã«å½ããã®æ¿èªãå¿ è¦ã§ãã£ããã4æ20æ¥ã«ãã®ãã¹ã¦ã®æ¯æãå¾ãããã®ã ã æ¥æ¬ãTPPã«å çããå ´åãã©ã®ãããªåé¡ã®çºçãäºæ³ãããã®ãã欧å·ã®é£èå½è£ åé¡ãæ¯ãè¿ããªããèãã¦ã¿ããã TPPã¨ãã®åé¡ç¹ TPPã¯ã貿æèªç±åãç®æããåå ã®é¢ç¨ãã»ã¼ã¼ãã«ããåãçµã¿ã§ãããæ¥æ¬ã®äº¤æ¸åå æ¿èªã®æ¡ä»¶ã¨ãã¦ããã¥ã¼ã¸ã¼ã©ã³ããã«ããã¯ãç±³å½ã¨åæ§ã«èªåè»ã®é¢ç¨æ¤å»ããªãã¹ãå¾ãåãã«ããããæ±ãã¦ããã ä¸æ¹ãæ¥æ¬ã«ã¨ã£ã¦ã®æ¸æ¡äºé ã¯å®ä¾¡ãªä½ç©ãè¼¸å ¥ãããæ¥æ¬å½å ã®è¾²æ¥ã«ãã¡ã¼ã¸ãåºããã¨ã ãã¾ããéºä¼åçµã¿
æç©ã®åç²ãªã©ã«æ¬ ãããªãããããã®æ¸å°ã§è¾²æ¥ã«è¢«å®³ãåºãã£ã¦ããäºæ ãåãã¦ãEUï¼ã¨ã¼ãããé£åã¯ï¼ï¼æ¥ãããããæ¸å°ã®åå ã®ï¼ã¤ã¨ææããã¦ããè¾²è¬ï¼ç¨®é¡ã®ä½¿ç¨ãããã¨ãï¼ï¼æããï¼¥ï¼µå ¨åã§ç¦æ¢ãããã¨ã決ãã¾ããã ã¨ã¼ãããã§ã¯è¿å¹´ãããããã®æ°ã®æ¸å°ãåé¡ã«ãªã£ã¦ãããèèã®çç£ãæ¸ã£ã¦ããã ãã§ãªããæç©ãªã©è¾²ä½ç©ã®åç²ãã§ããªããªããã¨ã«ãã£ã¦è¾²æ¥ã¸ã®è¢«å®³ãæ·±å»åãã¦ãã¾ãã ãããåãã¦ãEUã®å·è¡æ©é¢ã§ããã¨ã¼ãããå§å¡ä¼ã¯ï¼ï¼æ¥ãããããæ¸å°ã®åå ã®ï¼ã¤ã¨ææããã¦ããããªãã³ããã¤ãç³»ã®è¾²è¬ï¼ç¨®é¡ã«ã¤ãã¦ããã®ä½¿ç¨ããã¨ãï¼ï¼æããï¼¥ï¼µå ¨åã§ç¦æ¢ãããã¨ã決ãã¾ããã ãã ãããããã®æ¸å°ã«ã¤ãã¦ã¯ãå°ççè¦æ¨¡ã®æ°åå¤åãå¯çè«ãªã©ãè¤åçãªè¦å ãææããã¦ãããããEUã¯ãä»åç¦æ¢ãããè¾²è¬ãããããã®æ¸å°ã«ã©ã®ç¨åº¦å½±é¿ãä¸ãã¦ããã®ããããã«ç 究ãé²ããç¦æ¢ãç¶
2013-03-15 ããã®æ¾å°ç·æåæ§ã«ã¤ãã¦ã®æ°ããå ±åæ¸ HPA New report on human sensitivity to radiation 14 March 2013 http://www.hpa.org.uk/NewsCentre/NationalPressReleases/2013PressReleases/130314Newreportonhumansensitivitytoradiation/ HPAã®ç¬ç«ããã¤ãªã³åæ¾å°ç·ã«é¢ããå©è¨å§å¡ä¼ï¼AGIRï¼ã®å ±åæ¸â¦ 2013-03-15 ASAè£å® ASA ASA Adjudication on CNM The College of Naturopathic Medicine Ltd 13 March 2013 http://www.asa.org.uk/Rulings/Adjudications/2013/3
第ï¼ï¼åéºä¼åçµæãçç©ã®ãã¤ãªã»ã¼ããã£ã«é¢ããå½éã·ã³ãã¸ã¦ã ï¼ï¼æ ç±³å½ï¼ åå å ±å ç¾å¨ãä¸çã§çç£ããããã¦ã¢ãã³ã·ã®ï¼åã®ï¼ãéºä¼åçµæããã¦ã¢ãã³ã·ã§ããããã¤ãºã§ã¯ããã®ï¼åã®ï¼ãéºä¼åçµæãä½ç©ã§å ãããã¦ãã¾ããããã¦ãé£æèªçµ¦çãï¼ï¼ï¼ ã§ããæ¥æ¬ã¯ããã®é£æã®åå以ä¸ãæµ·å¤ã§çç£ãããä½ç©ã«ä¾åãã¦ãã¾ããã¨ãã«é£¼æãå å·¥ç¨åæã¯ãéºä¼åçµæãä½ç©ã大è¦æ¨¡ã«æ ½å¹ããå½ããæ¥æ¬ã«è¼¸å ¥ããããããããæ¥å¸¸ã®é£çæ´»ã®ä¸ã§ãé£èãæ²¹ãªã©ã®ããã¡ã§ãéæ¥çã«éºä¼åçµæãä½ç©ãé£ã¹ã¦ãã¾ãã éºä¼åçµæãçç©ã®ãã¤ãªã»ã¼ããã£ï¼çç©å¦çå®å ¨æ§ï¼ã«é¢ããå½éã·ã³ãã¸ã¦ã (International Symposium on the Biosafety of Genetically Modified OrganismsãISBGMO) ã¯ããã®ãããªéºä¼åçµæãä½ç©ãåç©ã®å®å ¨æ§
Gï¼ã³ã¼ã³ã®çºããæ§èªããï¼ãç§å¦çã«ä¸ååãâEU Gï¼ã³ã¼ã³ã®çºããæ§èªããï¼ãç§å¦çã«ä¸ååãâEU ãããªã¥ãã»ã«æäºã欧å·é£åï¼ï¼¥ï¼µï¼ã®æ¬§å·é£åå®å ¨æ©é¢ï¼ï¼¥ï¼¦ï¼³ï¼¡ï¼ã¯ï¼æ¥ãã©ããå®é¨ã§éºä¼åçµã¿æãï¼ï¼§ï¼ï¼ãã¦ã¢ãã³ã·ã®çºããæ§ãææãããã©ã³ã¹ã®ç ç©¶å ±åã«ã¤ãã¦ãç§å¦çã«ä¸ååãªãã®ã ã¨ã®è¦è§£ã表æããã ãåé¡ã¨ãããã®ã¯ã米農æ¥ãã¤ãªå¤§æã¢ã³ãµã³ããéçºããEFSAãEUã«ããè¼¸å ¥ãæ¿èªããGï¼ãã¦ã¢ãã³ã·ãNKï¼ï¼ï¼ããï¼2012/10/05-07:53ï¼
ã風è©è¢«å®³ãã¨ã®éããç´¹ä»ãJCç·ç ã欧å·ã®ï¼äºä¾ãç¹å¥å ±å JCç·ç ã¯ã風è©è¢«å®³ã¨éã£ãã¨ã¼ãããã®è¾²æ¥ååçµåãã¨é¡ããã欧å·ååçµåã¬ã¿ã¼ãã®ç¹å¥å ±åæ¸ãæ¨å¹´æ«ã«çºè¡ããã æ¥æ¬ã®è¾²æ¥è ã¯åçºäºæ ã«ãã風è©è¢«å®³ã§è¦ããã§ãããã欧å·ã§ã¯é£ä¸æ¯äºä»¶ãªã©ã«ãã風è©è¢«å®³ã«è¾²åã¯ã©ã対å¿ãã¦ãããã示åãå¾ãããç¹å¥å ±åæ¸ã¯ï¼ä»¶ã®äºä¾ãã¾ã¨ããããã®ï¼é¨ãç´¹ä»ããã¨â¦ã ããã¤ãã2011å¹´ï¼æãç åæ§å¤§è ¸èã®é£ä¸æ¯ããã¤ãããå½å¤ã«ãåºããã風è©è¢«å®³ã§éèã売ããªããªã£ããã¨ã¸ããããã®è¼¸å ¥æ¤ç©ãç åèãéãã ã®ãåå ã¨ããããããã¤ãã®éæç©çç£è å£ä½ä¸å¤®ä¼(BVEÐ)ã¯ä¼å¡è¾²å®¶ã«å¯¾ããè£åéã®å¯¾è±¡åç®æ¡å¤§ãEUå½å±ã«è¦æ±ãã被害é¡ã®ç®å®ãç³è«æ¸é¡ã®ä½æãªã©ãã¹ã¦ã®ä½æ¥ã管çããã ããã対象åç®ã¯è¿½å ããããã®ã®è£åéé¡ã¯ã被害é¡ã®ï¼åã®ï¼ç¨åº¦ã ã£ããä¸æ¹ãåä¼ã¯æ¶è²»è ã®ä¿¡é ¼å復ã¸è³é
Gï¼ä½ç©ã®æ ½å¹ç¦æ¢ã¯éæ³ã¨è£å®ãä»æé«è£ ãã©ã³ã¹ã®æé«è£å¤æã«ãããå½åé¢ã¯11æ28æ¥ããã©ã³ã¹æ¿åºã®éºä¼åçµæãï¼ï¼§ï¼ï¼ä½ç©ã®å½å æ ½å¹ãç¦æ¢ä»¤ãéæ³ã§ããã¨ããè£å®ããã ããã ãã©ã³ã¹æ¿åºãå½å ã§ã®æ ½å¹ãç¦æ¢ããã®ã¯ï¼§ï¼ãã¦ã¢ãã³ã·Mon810ã§ãEUã§æ ½å¹ãèªãããã¦ããæ°å°ãªãGï¼ä½ç©ã®ä¸ã¤ããã©ã³ã¹ã§ã08å¹´ã«ãã®ç¦æ¢ä»¤ãåºãã¾ã§ã¯ãï¼ä¸2000haã§åæ¥æ ½å¹ããããã10ä¸haè¦æ¨¡ã¾ã§æ¡å¤§ããã¨äºæ¸¬ããã¦ããã ãã©ã³ã¹æ¿åºã¯ã08å¹´ã«å¥åº·ããã³ç°å¢ã¸ã®ãªã¹ã¯ãçç±ã«æ ½å¹ãç¦æ¢ãããã欧å·å¸æ³è£å¤æï¼ï¼¥ï¼£ï¼ªï¼ã¯ãã®ï¼æã«ãGï¼ä½ç©ã®å¥åº·ããã³ç°å¢ã¸ã®ãªã¹ã¯ã示ããããªãç§å¦çãªæ ¹æ ããã©ã³ã¹æ¿åºã示ããã¨ãã§ããããããã£ãEUã®èªå¯ãåæ¢ããããã«å¿ è¦ãªæé ã«ãããã£ãããªãã¨ããã®ç¦æ¢ä»¤ãéæ³ã¨è£å®ããã ãã©ã³ã¹æé«è£ã®è£å®ã¯ãã®ï¼¥ï¼£ï¼ªã®è£å®ãæ¯æãã¦ä¸ããããã®ã§ã
å·çè æ£®ç° æºæ¨¹ ä¹å·å¤§å¦è¾²å¦é¨åæ¥å¾ãé£åä¼ç¤¾ç 究æãæ¥çèªãæ°é調æ»ä¼ç¤¾çãçµã¦ãç¾å¨ã¯ããªã¼ã®æ¶è²»çæ´»ã³ã³ãµã«ã¿ã³ããã©ã¤ã¿ã¼ã é£å表示ã»è æ£®ç° æºæ¨¹ 2011å¹´12æ12æ¥ æææ¥ ãã¼ã¯ã¼ãï¼ã¢ã¬ã«ã®ã¼ æ é¤ æ·»å ç© é£å表示 é£æå EUã®æ¬§å·è°ä¼ã¯2011å¹´11æ22æ¥ä»ã§ãæ°ããé£å表示ã«ã¼ã«ã¨ãªãä¸è¬é£å表示è¦å(No 1169/2011)ãå®å ±ã«æ²è¼ãããEUã«ãããé£å表示ã®æ³å¾ã¯ããã¹ã¦ã®é åã®é£åã«æ¨ªæçã«é©ç¨ãããæ°´å¹³çãªæ³å¾ã¨ãç¹å®ã®é£åé åã«é©ç¨ãããåå¥é£åãã¨ã®åç´çæ³å¾ã®äºã¤ãããªããä»åå®ããããã®ã¯ãåè ã®æ°´å¹³çãªæ³å¾ã«è©²å½ãããã®ã ãè¦åã®å¤§åã¯ããããã3å¹´ãçµã¦ããåå½ã§é©ç¨ãããã EUã«ããã¦æ¨ªæçãªé£å表示ã«ã¼ã«ãå®ããã®ã¯1970年代å¾åããã§ãEUåå ã§åæ»ã«é£åãæµéãããã¨ãæ¶è²»è ãä¿è·ãããã¨ãç®çã¨ãã¦ã¹ã¿ã¼ããããã
2011-10-06 ASAè£å®ããã¡ãªãã·ã¼ï¼21ä¸ç´ã®å»è¬å ASA ASA Adjudication on Homeopathy: Medicine for the 21st Century 5 October 2011 http://www.asa.org.uk/ASA-action/Adjudications/2011/10/Homeopathy,-c-,-Medicine-for-the-21st-Century/SHP_ADJ_139800.aspx ãã¡ãªãã·ã¼æ¨é²å£ä½ã«ããéèªåºåã®è¦åºâ¦ 2011-10-06 EFSAã®çç±ã¤ãæè¦æ¸ï¼çé£ç¨ããã¦ãã¯ã¤ã³ç¨ããã¦ããããããã¹ããããã¼ãå·ãã¨é£ã¹ãããã«ããã£ã®ãã§ã³ãã©ã¶ãã³ã®MRLè¨å® EFSA Reasoned opinion of EFSA: Setting of MRLs for fenpyrazamine
ãªãªã¼ã¹ãé害æ å ±ãªã©ã®ãµã¼ãã¹ã®ãç¥ãã
ææ°ã®äººæ°ã¨ã³ããªã¼ã®é ä¿¡
å¦çãå®è¡ä¸ã§ã
j次ã®ããã¯ãã¼ã¯
kåã®ããã¯ãã¼ã¯
lãã¨ã§èªã
eã³ã¡ã³ãä¸è¦§ãéã
oãã¼ã¸ãéã
{{#tags}}- {{label}}
{{/tags}}